Table 1.

Clinical drug trials involving MYC in breast cancer patients

	Trial number	Trial phase	Patients	Interventions	Status
1	NCT00898898	Not Applicable	Primary HER2 positive breast cancer	Other: diagnostic laboratory biomarker analysis	Completed
2	NCT01676753	Phase I	Advanced or Metastatic Breast Cancer; Triple Negative Breast Cancer.	Drugs: Dinaciclib; Pembrolizumab	Active, not recruiting
3	NCT00740532	Not Applicable	Metastatic Breast Cancer	Genetic: Gene mutation analyses and FISH	Completed
4	NCT01534455	Phase II	Metastatic Breast Cancer	Drugs: Lapatinib + 1,23 mg Eribulin; Lapatinib + 1,76 mg Eribulin	Terminated
5	NCT03950570	Phase I	Metastatic Breast Cancer	Drug: Paclitaxel	Recruiting
6	NCT02651844	Not Applicable	Breast Cancer with ratios of PRA/PRB higher than 1.5 and PR higher than 50%.	Drug: Mifepristone	Active, not recruiting
7	NCT01104571	Phase III	Early Breast Cancer	Biological: trastuzumab; Drug: lapatinib ditosylate; Other: laboratory biomarker analysis;Procedures: adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery.	Active, not recruiting
8	NCT03085368	Phases II & III	HER2-positive Breast Cancer	Drug: lapatinib/trastuzumab	Recruiting
9	NCT00553358	Phase III	HER2/ErbB2 Positive Primary Breast Cancer	Drug: Lapatinib;Biological: Trastuzumab; Drug: Paclitaxel.	The pCR rate was significantly higher in the group given lapatinib and trastuzumab. No significant difference in pCR between the lapatinib and the trastuzumab groups 66.